Prometheus Biosciences (NASDAQ: RXDX)
Some price data may be temporarily unavailable.
Prometheus Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Prometheus Biosciences Company Info
Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA .
News & Analysis
Why Prometheus Biosciences Stock Is Skyrocketing This Week
There's nothing like a big buyout to send a clinical-stage biotech stock soaring higher.
Why Shares of Prometheus Biosciences Are Soaring Monday
Merck's $10.8 billion buyout offer sent the clinical-stage biotech stock higher.
Is Prometheus Biosciences a Good Stock to Buy Right Now?
This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead.
Why Shares of Prometheus Biosciences Are Soaring This Week
The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy.
Why Shares of Prometheus Biosciences Slumped This Week
The company's lead pipeline candidate is facing competition from a Pfizer-backed drug.
Can This Tiny Biotech Take On Pfizer?
A little-known biotech chasing Pfizer's tail could soon skyrocket.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.